title: Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
abstract: BACKGROUND
  Reported studies have showed that Thrombin Activatable Fibrinolysis Inhibitor (TAFI) may be associated with an increased risk of venous thromboembolism. But the relation of VT with TAFI gene SNPs could not be clearly demonstrated. Thus, we conducted a meta-analysis to analyze the associations between three TAFI variants -438G/A, 505G/A and 1040C/T and the risk of venous thrombosis.
  
  
  METHODS
  We carried out a systematic search to obtain all the eligible studies published before 30th October 2014. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed to assess the association.
  
  
  RESULTS
  13 eligible studies were enrolled including 2321 patients and 2464 controls. There was a significant association between 505G/A and the risk of VTD under all models except recessive model (G vs. A: OR=1.13, 95% CI: 1.02, 1.26; GG vs. AA:OR=1.47, 95% CI: 1.14, 1.88; GA vs. AA: OR=1.36, 95% CI: 1.06, 1.73; GG+GA vs. AA: OR=1.41, 95% CI: 1.12, 1.77). Similarly, obvious relationship was observed in subgroup analyses in light of type of disease and ethnicity. Likewise, for 1040C/T variant, significant associations were identified under homozygote, heterozygote and dominant models (CC vs. TT: OR=1.65, 95% CI: 1.06, 2.59; CT vs. TT: OR=1.55, 95% CI: 1.19, 2.03; CC+CT vs. TT: OR=1.55, 95% CI: 1.20, 2.00). Sub-analysis presented significant associations in non-CVT and non-Asian group under homozygote, heterozygote, and dominant models and CVT group in recessive model.
  
  
  CONCLUSIONS
  This meta-analysis showed that -438G/A variant was not associated with the incidence of venous thrombosis. But in non-Asian populations, G allele and GG genotype of 505G/A may increase the risk of venous thrombosis diseases. GG genotype of 505G/A and one C carrier (CC and CT) of 1040C/T gave rise to the development of venous thrombosis diseases except CVT. Additionally, the heterozygote CT may be a potential contributing factor of gene effect in venous thrombosis.
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Qian
authors.affiliation: Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Heng
authors.initials: H
authors.lastname: Wan
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Fangyong
authors.initials: F
authors.lastname: Fu
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Jingbo
authors.initials: J
authors.lastname: Lu
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Zhiqi
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
authors.forename: Zhengjun
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: specificgz@163.com.
authors.forename: Hao
authors.initials: H
authors.lastname: Liu
mesh_terms: D025901:Carboxypeptidase B2 / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D011655:Pulmonary Embolism / Q000235:genetics; D044469:Racial Groups / Q000235:genetics; D020246:Venous Thrombosis / Q000235:genetics* / Q000503:physiopathology
chemical_list: D025901:Carboxypeptidase B2
keywords: Meta-analysis; Polymorphisms; Thrombin activatable fibrinolysis inhibitor; Venous thrombosis